NEW KCRS26 — Kidney Cancer Research Summit: top KOL voices, trial buzz & every slide, decoded View Full Coverage →
FDA APPROVED · BLADDER CANCER

KEYNOTE-B15 / EV-304 Trial

Perioperative enfortumab vedotin + pembrolizumab (Padcev + Keytruda) is now FDA-approved (July 10, 2026) for adult muscle-invasive bladder cancer patients who are radical-cystectomy candidates, regardless of cisplatin eligibility — based on EV-304/KEYNOTE-B15 (EFS HR 0.53; pCR 55.8% vs. 32.5%), the first platinum-free regimen to beat chemo in ~25 years.

FDA Approved — Jul 10, 2026Perioperative MIBCPadcev + KeytrudaASCO GU 2026 (#GU26)
Discover KOL Sentiment on KEYNOTE-B15 →View EV-304 on ClinicalTrials.gov →
At a Glance

KEYNOTE-B15 / EV-304 Key Takeaways

Design - Phase 3 perioperative enfortumab vedotin + pembrolizumab vs gemcitabine/cisplatin, MIBC radical-cystectomy candidates (NCT04700124 / EV-304).

EFS (co-primary) - HR 0.53 (95% CI 0.41-0.70); 24-month EFS 79.4% vs 66.2%.

pCR (co-primary) - 55.8% with EV + pembrolizumab vs 32.5% with chemotherapy.

OS - HR 0.65 (95% CI 0.48-0.89) - about a 35% reduction in risk of death; both medians not reached.

Safety - Grade >=3 AEs 75.7% vs 67.2%; profile consistent with the individual agents, no new safety signals.

Regulatory - FDA approved July 10, 2026 - first platinum-free perioperative regimen to beat cisplatin chemotherapy in MIBC in ~25 years.

Sponsor / drug - Astellas + Pfizer (Seagen) + Merck; Padcev + Keytruda.

Compiled and reviewed by the KOL Pulse research team, led by Brian Shields, Founder, KOL Pulse. Last updated July 21, 2026.

Influence Leaders

Top KOLs Discussing KEYNOTE-B15 / EV-304

Tom Powles
Tom Powles
@tompowles1
17.6K impressions
Marta Orozco Belinchon
Marta Orozco Belinchon
@OrozcoBelinchon
6.3K impressions
Dr Amol Akhade
Dr Amol Akhade
@SuyogCancer
5.7K impressions
Javier Puente
Javier Puente
@docjavip
4.9K impressions
Jacob Plieth
Jacob Plieth
@JacobPlieth
4.8K impressions
Dra. María Natalia Gandur Quiroga
Dra. María Natalia Gandur Quiroga
@nataliagandur
4K impressions
Free Access · KOL Pulse Intelligence

Track oncology’s top KOLs in your specialty

Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:

  • ✓Enhanced KOL profiles
  • ✓Pharma influence & potential advisory-board patterns
  • ✓2025 Open Payments financial analysis
  • ✓Social-media sentiment & trend signals
Get free access — pick your specialty
Choose the tumor types you follow. No cost, unsubscribe anytime.
Conference Presentations

KEYNOTE-B15 / EV-304 Key Slides & Visuals

Official trial slides and relevant visuals shared by KOLs at ASCO GU 2026 (#GU26). Click any image to expand.

Tom Powles
Tom Powles @tompowles1
KEYNOTE-B15 / EV-304 Data
9.9K impressions · 170 likes · Feb 27, 2026
View on X ↗
KEYNOTE-B15 / EV-304 slide
Click to expand
[Slide 1] KN905/EV303 B15/EV304 (n=808) NIAGARA (N=1063) EVPx3 -> cystectomy EVPx4 cystectomy Gem/Cis/Durva x4-> EVPx6 (P to 1yr) EVPx5 (P to 1yr) cystectomy (D to 1yr) The Ur migos™ R R R Gem/cisx4 Gem/cisx4 cystectomy cystectomy cystectomy Median follow up 26 months 33months 42 months %T2/%ctDNA+ve 17%/NA 20%/NA 40%/56% % cystectomy 87% 87% 88% % started/completed 66%/25% (6% ongoing) 56%/51% 71%/54% adjuvant therapy pCR rates 56% vs 33% 57% vs 9% 37% vs 27% 2 yr EFS 75% vs 39% 79% vs 66% 68% vs 60% EFS HR 0.40 (0.38-0.57) 0.53 (0.41-0.70) 0.68 (0.56-0.82) 2 yr os (study/control) 80% vs 63% 87% vs 81% 82% vs 75% os HR 0.50 (0.33-0.74) 0.65 (0.48-0.89) 0.75 (0.59-0.93) G3/4 AEs TRAE=45% TEAEs=63% vs 48% TRAEs=41% vs 41%
Tom Powles
Tom Powles @tompowles1
KEYNOTE-B15 / EV-304 Data
7.7K impressions · 131 likes · Feb 27, 2026
View on X ↗
KEYNOTE-B15 / EV-304 slide
Click to expand
KEYNOTE-B15 / EV-304 slide
Click to expand
KEYNOTE-B15 / EV-304 slide
Click to expand
KEYNOTE-B15 / EV-304 slide
Click to expand
[Slide 1] KEYNOTE-B15/EV-304 Study (NCT04700124) Key Eligibility Criteria Enfortumab vedotin 1.25 mg/kg Enfortumab vedotin 1.25 mg/kg Adults with MIBC N = 405 d1 and d8 IV Q3W 4 cycles d1 and d8 IV Q3W 5 cycles + + Clinical stage T2-T4aN0M0 or Pembrolizumab 200 mg d1 Pembrolizumab 200 mg d1 T1-T4aN1M0 by central assessment R 1:1 IV Q3W 4 cycles Urothelial histology ≥50% Eligible for RC + PLND Cisplatin 70 mg/m² d1 IV Q3W 4 cycles RC + PLND IV Q3W 13 cycles Did not meet any Galsky criteria for + Observationᵇ cisplatin ineligibility N = 403 Gemcitabine 1000 mg/m² ECOG PS 0-1 d1 and d8 IV Q3W 4 cycles Stratification Factors PD-L1 status (CPS ≥10 vs. <10)a Primary endpoint: Event-free survival (EFS) by BICR Clinical stage (T2N0 vs. T3/T4aN0 VS. T1-4aN1) Key secondary endpoints: OS and pathological complete response (pCR; pTONO, i.e. absence of viable tumor in examined tissue from surgery) by central pathologist review Geographic region (US vs. EU VS. Most of World) Other secondary endpoints include: Safety BICR, blinded independent central review; CPS, combined positive score; IV, intravenous; Q3W, every 3 weeks. "Assessed by PD-L1 IHC 22C3 pharmDx (Agilent, Carpinteria, CA); CPS = # PD-L1-staining cells (tumor cells, lymphocytes, and macrophages) + total # viable tumor cells x 100. As of Feb 2023, adjuvant nivolumab was permitted when clinically indicated and regionally available. Data cutoff date: 27 October 2025 --- [Slide 2] Primary Endpoint: EFS by BICR ITT Population EV + pembro Cis + gem N = 405 N = 403 100 Events, n (%) 87 (21.5) 146 (36.2) 90 86.0% 79.4% Median, mo (95% CI) NR (NR-NR) 48.5 (43.3-NR) 80 Event-free survival, % 70 60 75.4% 66.2% 50 40 30 20 HR 0.53, 95% CI 0.41-0.70, 1-sided P <.0001* 10 0 0 6 12 18 24 30 36 42 48 54 Months No. at Risk EV + pembro 405 351 317 303 257 154 100 63 23 0 Cis + gem 403 350 286 259 216 131 70 45 16 0 Data cutoff date: 27 October 20 not reached. . denotes statistical significance (one-sided boundary 0.0082). --- [Slide 3] Key Secondary Endpoint: OS ITT Population 100 93.1% 86.9% 90 80 89.6% 70 81.3% Overall survival, % 60 50 EV + pembro Cis + gem N = 405 N = 403 40 Events, n (%) 69 (17.0) 99 (24.6) 30 Median, mo (95% CI) NR (NR-NR) NR (NR-NR) 20 HR 0.65, 95% CI 0.48-0.89, 10 1-sided P =.0029* 0 0 6 12 18 24 30 36 42 48 54 Months No. at Risk EV + pembro 405 396 377 361 325 215 142 90 34 0 Cis + gem 403 392 358 338 295 201 119 67 29 0 In total, 44/87 (50.6%) of pts with an EFS event in the EV + pembro arm and 86/146 (58.9%) of pts with an EFS event in the cis + gem arm received any subsequent systemic therapy Data cutoff date: 27 October 2025 NR, not reached. . denotes statistical significance (one-sided boundary 0.0038). --- [Slide 4] Key Secondary Endpoint: pCR by Central Pathology Review ITT Population 100 Estimated differenceᵃ 23.4% (95% CI 16.7-29.8) EV + pembro Cis + gem N = 405 N = 403 1-sided P <.0001* 80 pCR, n 226 131 pCR, % (95% CI) 60 H pCR rate, % 55.8 32.5 (95% CI) (50.8-60.7) (28.0-37.3) 40 H pCR: defined as absence of viable tumor in examined tissue from RC + PLND (pTONO) 20 Pts who discontinued study therapy prior to definitive surgery were classified as non-responders 0 Out of pts who underwent surgery, 226/351 (64.4%) in the EV + Cis + EV + pembro arm and 131/361 (36.3%) in the cis + gem pembro gem arm had pCR * denotes statistical significance (one-sided boundary 0.001). Data cutoff date: 27 October 202 "Based on stratified Miettinen and Nurminen method.
Marta Orozco Belinchon
Marta Orozco Belinchon @OrozcoBelinchon
KEYNOTE-B15 / EV-304 Data
6.3K impressions · 51 likes · Mar 21, 2026
View on X ↗
KEYNOTE-B15 / EV-304 slide
Click to expand
KEYNOTE-B15 / EV-304 slide
Click to expand
KEYNOTE-B15 / EV-304 slide
Click to expand
[Slide 1] des 21 21 2026 2026 2026 GUCANCERS ... do MVOID+ TOPICS TRENDING --- [Slide 2] Patient population: Primary endpoints eligible MIBC Durva+GC arm Neoadjuvant Adjuvant EFS* (cT2-T4aN0/1M0) n=533 Durva 1500 mg IV Durvalumab 1500 mg IV pCR' UC or UC with divergent differentiation or histologic subtypes Gemcitabine+Cisplatin Q4W, 8 cycles Key secondary endpoint CrCl of >40 mL/min Q3W, 4 cycles os R RC Secondary endpoints Stratification: 1:1 MFS Clinical tumour stage (T2N0 vs >T2N0) Renal function (CrCl 260 mL/min vs >40- N=1066 DSS Gemcitabine+cisplatin No treatment <60 mL/min) n=530 Safety PD-L1 status (high vs low/negative Immune-mediated AEs GC comparator arm expression) Patient population: EV+pembro arm Adults with MIBC EV 1.25 mg/kg EV 1.25 mg/kg Clinical stage T4aNOMC or 11 T4aN1M0 by n=405 01 and D8 IV Q3W 4 cycles Primary endpoint D1 and D8 IV Q3W5 cycles central EFS** Urothelial histology 250% Pembro 200 mg D1 Pembro 200 mg D1 Eligible of PLND Key secondary endpoints IV Q3W 4 cycles Did not meet any Galsky criteria for cisplatin ineligibility PLND IV Q3W 13 cycles ECOG PS0-1 R os 1:1 Cisplatin 70 mg/m2 pCR" Stratification: 01 IV Q3W 4 cycles Safety PO-L1 status (CPS is <10)* N=808 + Observation Clinical stage (T2ND as T3/T4aND n 71-4aN1) n=403 Gemcitabine 1000 mg/m2 Immune-mediated AEs Geographic region (USA vs tu 93 Most of the World) GC arm D1 and D8 IV Q3W 4 cycles Patient population: Neoadjuvant Adjuvant Arm A MIBC cT2-T4aN0- P (n=210) Pembro Q3W x 3 cycles Pembro Q3W X 14 cycles 1M0 or cT1-4aN1M0 Primary endpoint: Ineligible for EFS P+EV VS observation cisplatin KN-905/ Cis-refusal Arm B R Observation Cystectomy Secondary endpoints: Observ Observation' EV-303⁴ 1:1 EFS P VS observation Stratification: N=344 Tumour stage OS, pCR, DFS, pDS, safety Cis-ineligible vs Arm C Pembro Q3W X 3 cycles Pembro Q3W X 14 cycles and tolerability cis-refusal P+EV - EV Q3W X 3 cycles EV Q3W X 6 cycles --- [Slide 3] Can ctDNA guide adjuvant immunotherapy after NAC or in cis-ineligible patients? IMvigor011 study design Surveillance Screening Treatment Follow-up ctDNA monitoring until 1 y post-cystectomy* Atezolizumab (1680 mg) IV q4w for up to 1y MIBC within 6-24 weeks of Confirm no evidence of R Treatment radical cystectomy radiographic disease 2:1 follow-up Placebo Histologically confirmed IV q4w for up to y (y)pT2-T4aNOMO or 6-weekly ctDNA+ (y)pTO-T4aN+M0 ctDNA testing any time urothelial cancer No evidence of 12-weekly radiographic disease radiographic ctDNA- imaging until 1y Prior neoadjuvant chemotherapy permitted No treatment Surveillance ECOG PS 0-2 follow-up Repeat testing if ctDNA- Primary endpoint: INV-assessed DFS Key secondary endpoint: OS Powles T, et al. NEJM 2025
Javier Puente
Javier Puente @docjavip
KEYNOTE-B15 / EV-304 Data
4.9K impressions · 55 likes · Feb 27, 2026
View on X ↗
KEYNOTE-B15 / EV-304 slide
Click to expand
KEYNOTE-B15 / EV-304 slide
Click to expand
KEYNOTE-B15 / EV-304 slide
Click to expand
KEYNOTE-B15 / EV-304 slide
Click to expand
[Slide 1] Galsky KNB15 ASCO GU 2026 ASCO Genitourinary Cancers Symposium Neoadjuvant and Adjuvant Enfortumab Vedotin Plus Pembrolizumab for Participants With Muscle-Invasive Bladder Cancer Who Are Eligible for Cisplatin: Randomized, Open-Label, Phase 3 KEYNOTE-B15 Study Matthew D. Galsky1, Begoña Pérez-Valderrama², Marco Maruzzo³, Albert Font4, Tudor Ciuleanu⁵, Jonathan Chatzkel⁶, Takuya Koie⁷, Christopher Hoimes⁸, Javier Puente⁹, Yousef Zakharia¹⁰, Eli Rosenbaum¹¹, Katharina Boehm¹², Yohann Loriot¹³, Jens Bedke¹⁴, Thomas B. Powles¹⁵; Heidi S. Wirtz¹⁶, Michael Mihm17, Qinlei Huang¹⁸, Aljosja Rogiers¹⁸, Blanca Homet Moreno¹⁸, Alfonso Gómez de Liaño19 11cahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA; 2Hospital Universitario Virgen del Rocio, Seville, Spain; 31stituto Oncologico Veneto IRCCS-Oncologia Medica 1. Padova, Italy: Catalan Institute of Oncology (ICO) Badalona, Barcelona, Spain; 5Institutul Oncologic Prof. Dr. on Chiricuta Cluj-Napoca, Cluj-Napoca, Romania; University of Florida, Gainesville, FL, USA; [current affiliation] Moffitt Cancer Center, Tampa, FL, USA; Gifu University Hospital, Gifu, Japan; Duke University Medical Center, Durham, NC, USA; Hospital Clinico Universitario San Carlos de Madrid, Madrid, Spain; 10Mayo Clinic, Phoenix, AZ, USA; "Rabin Medical Center-Oncology, Petah Tikva, Israel; 12University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany, 13Institut Gustave Roussy, Université Paris-Saclay, Villejuif, France; 14Eva Mayr-Stihl Cancer Center, Klinikum Stuttgart, Stuttgart, Germany; 15Barts Health NHS Trust and the Royal Free NHS Foundation Trust, Barts Cancer Institute, and Queen Mary University of London, London, United Kingdom; "Pfizer, Bothell, WA, USA; 17Astellas Pharma Inc. Northbrook, IL, USA; 18Merck & Co., Inc., Rahway, NJ, USA; 19Complejo Hospitalario Universitario Insular-Materno Infantil de Gran Canaria, Las Palmas, Spain ASCO Genitourinary #GU26 PRESENTED BY: Matthew D. Galsky ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY Cancers Symposiu Presentation is property of the author and ASCO Permission required for reuse, contact permissions@asco.org KNOWLEDGE CONQUERS CANCER CC ... --- [Slide 2] Galsky KNB15 ASCO GU 2026 KEYNOTE-B15/EV-304 Study (NCT04700124) Key Eligibility Criteria Enfortumab vedotin 1.25 mg/kg Enfortumab vedotin 1.25 mg/kg Adults with MIBC N = 405 d1 and d8 IV Q3W 4 cycles d1 and d8 IV Q3W 5 cycles + + Clinical stage T2-T4aNOM0 or Pembrolizumab 200 mg d1 Pembrolizumab 200 mg d1 T1-T4aN 1M0 by central assessment R 1:1 IV Q3W 4 cycles Urothelial histology ≥50% Eligible for RC + PLND Cisplatin 70 mg/m2 RC + PLND IV Q3W 13 cycles d1 IV Q3W4 cycles Did not meet any Galsky criteria for + Observationᵇ cisplatin ineligibility N = 403 Gemcitabine 1000 mg/m2 ECOG PS 0-1 d1 and d8 IV Q3W 4 cycles Stratification Factors PD-L1 status (CPS ≥10 VS. <10)ᵃ Primary endpoint: Event-free survival (EFS) by BICR Clinical stage (T2N0 VS. T3/T4aN0 VS. T1-4aN1) Key secondary endpoints: OS and pathological complete response (pCR; pTONO, i.e. absence of viable tumor in examined tissue from surgery) by central pathologist review Geographic region (US vs. EU VS. Most of World) Other secondary endpoints include: Safety BICR, blinded independent central review; CPS, combined positive score; IV, intravenous; Q3W, every 3 weeks. *Assessed by PD-L1 IHC 22C3 pharmDx (Agilent, Carpinteria, CA); CPS = # PD-L1-staining cells (tumor cells, lymphocytes, and macrophages) - total # viable tumor cells X 100. As of Feb 2023, adjuvant nivolumab was permitted when clinically indicated and regionally available. Data cutoff date: 27 October 2025 --- [Slide 3] Galsky KNB15 ASCO GU 2026 Primary Endpoint: EFS by BICR ITT Population EV + pembro Cis + gem N = 405 N = 403 100 Events, n (%) 87 (21.5) 146 (36.2) 90 86.0% 79.4% Median, mo (95% CI) NR (NR-NR) 48.5 (43.3-NR) 80 Event-free survival, % 70 60 75.4% 66.2% 50 40 30 20 HR 0.53, 95% CI 0.41-0.70, 1-sided P <.0001* 10 0 0 6 12 18 24 30 36 42 48 54 Months No. at Risk EV + pembro 405 351 317 303 257 154 100 63 23 0 Cis + gem 403 350 286 259 216 131 70 45 16 0 Data cutoff date: 27 October 2025 NR. not reached . denotes statistical significance (one-sided boundary 0.0082). --- [Slide 4] Galsky KNB15 ASCO GU 2026 Key Secondary Endpoint: OS ITT Population 100 93.1% 86.9% 90 80 89.6% 70 81.3% Overall survival, % 60 50 EV + pembro Cis + gem N = 405 N = 403 40 Events, n (%) 69 (17.0) 99 (24.6) 30 Median, mo (95% CI) NR (NR-NR) NR (NR-NR) 20 HR 0.65, 95% CI 0.48-0.89, 10 1-sided P =.0029* 0 0 6 12 18 24 30 36 42 48 54 Months No. at Risk EV + pembro 405 396 377 361 325 215 142 90 34 0 Cis + gem 403 392 358 338 295 201 119 67 29 0 In total, 44/87 (50.6%) of pts with an EFS event in the EV + pembro arm and 86/146 (58.9%) of pts with an EFS event in the cis + gem arm received any subsequent systemic therapy Data cutoff date: 27 October 2025 NR. not reached. . denotes statistical significance (one-sided boundary 0.0038).
David H Aggen, MD PhD
David H Aggen, MD PhD @Dr_Aggen
KEYNOTE-B15 / EV-304 Data
2.9K impressions · 42 likes · Mar 1, 2026
View on X ↗
KEYNOTE-B15 / EV-304 slide
Click to expand
KEYNOTE-B15 / EV-304 slide
Click to expand
KEYNOTE-B15 / EV-304 slide
Click to expand
KEYNOTE-B15 / EV-304 slide
Click to expand
[Slide 1] KEYNOTE-B15/EV-304 Study (NCT04700124) Key Eligibility Criteria Enfortumab vedotin 1.25 mg/kg Enfortumab vedotin 1.25 mg/kg Adults with MIBC N = 405 d1 and d8 IV Q3W 4 cycles d1 and d8 IV Q3W 5 cycles + + Clinical stage T2-T4aN0M0 or Pembrolizumab 200 mg d1 Pembrolizumab 200 mg d1 T1-T4aN1M0 by central assessment R 1:1 IV Q3W 4 cycles Urothelial histology >50% Eligible for RC + PLND Cisplatin 70 mg/m2 d1 IV Q3W 4 cycles RC + PLND IV Q3W 13 cycles Did not meet any Galsky criteria for + Observation cisplatin ineligibility N = 403 Gemcitabine 1000 mg/m2 ECOG PS 0-1 d1 and d8 IV Q3W 4 cycles Stratification Factors PD-L1 status (CPS ≥10 vs. <10)a Primary endpoint: Event-free survival (EFS) by BICR Clinical stage (T2N0 vs. T3/T4aN0 vs. T1-4aN1) Key secondary endpoints: OS and pathological complete response (pCR; pTONO, i.e. absence of viable tumor in examined tissue from surgery) by central pathologist review Geographic region (US vs. EU VS. Most of World) Other secondary endpoints include: Safety BICR, blinded independent central review; CPS, combined positive score; IV, intravenous; Q3W, every 3 weeks. "Assessed by PD-L1 IHC 22C3 pharmDx (Agilent, Carpinteria, CA); CPS = # PD-L1-staining cells (tumor cells, lymphocytes, and macrophages) + total # viable tumor cells X 100. As of Feb 2023, adjuvant nivolumab was permitted when clinically indicated and regionally available. Data cutoff date: 27 October 2025 --- [Slide 2] Primary Endpoint: EFS by BICR ITT Population EV + pembro Cis + gem N = 405 N = 403 100 Events, n (%) 87 (21.5) 146 (36.2) 90 86.0% 79.4% Median, mo (95% CI) NR (NR-NR) 48.5 (43.3-NR) 80 Event-free survival, % 70 60 75.4% 66.2% 50 40 30 20 HR 0.53, 95% CI 0.41-0.70, 1-sided P <.0001* 10 0 0 6 12 18 24 30 36 42 48 54 Months No. at Risk EV + pembro 405 351 317 303 257 154 100 63 23 0 Cis + gem 403 350 286 259 216 131 70 45 16 0 Data cutoff date: 27 October 2025 NR, not reached. * denotes statistical significance (one-sided boundary 0.0082). --- [Slide 3] EFS by BICR in Key Subgroups ITT Population Events/Participants EV + pembro Cis + gem HR (95% CI) Overall 87/405 146/403 0.53 (0.41-0.70) Age <65 years 24/158 51/156 0.43 (0.27-0.70) >65 years 63/247 95/247 0.59 (0.43-0.82) Sex Male 69/327 113/327 0.56 (0.42-0.76) Female 18/78 33/76 0.47 (0.26-0.83) Race White 73/329 119/314 0.53 (0.40-0.71) All others 14/76 27/87 0.53 (0.28-1.01) Region United States 8/59 14/59 0.58 (0.25-1.39) European Union 48/206 86/205 0.47 (0.33-0.68) Most of world 31/140 46/139 0.65 (0.41-1.02) PD-L1 CPS ≥10 43/233 74/230 0.53 (0.36-0.77) <10 43/171 72/173 0.54 (0.37-0.79) Tumor stage by BICR T2N0 15/79 19/77 0.76 (0.39-1.51) T3/T4aN0 65/293 110/293 0.54 (0.40-0.73) T1-4aN1 7/33 17/33 0.30 (0.12-0.72) 0.05 0.25 0.5 1.0 2.0 4.0 Favors EV + pembro Favors cis + gem Data cutoff date: 27 October 2025 bgroup levels with <10 events across both treatment arms were not included in forest plots. --- [Slide 4] Key Secondary Endpoint: OS ITT Population 100 93.1% 86.9% 90 80 89.6% 70 81.3% Overall survival, % 60 50 EV + pembro Cis + gem N = 405 N = 403 40 Events, n (%) 69 (17.0) 99 (24.6) 30 Median, mo (95% CI) NR (NR-NR) NR (NR-NR) 20 HR 0.65, 95% CI 0.48-0.89, 10 1-sided P =.0029* 0 0 6 12 18 24 30 36 42 48 54 Months No. at Risk EV + pembro 405 396 377 361 325 215 142 90 34 0 Cis + gem 403 392 358 338 295 201 119 67 29 0 In total, 44/87 (50.6%) of pts with an EFS event in the EV + pembro arm and 86/146 (58.9%) of pts with an EFS event in the cis + gem arm received any subsequent systemic therapy Data cutoff date: 27 October 2025 not reached. . denotes statistical significance (one-sided boundary 0.0038).
Community Discussion

KEYNOTE-B15 / EV-304 Top Tweets

Top tweets by impressions — click to view on X

Toni Choueiri, MD
Toni Choueiri, MD@DrChoueiri

Now, the combo of EV-Pembro is @US_FDA approved for all muscle-invasive bladder cancer @OncoAlert @AUC3_Official @Merck @BladderCancerUS @OncoBellmunt @bergsa83 @mouwlab

🟢 FDA Approval Jul 10, 2026
Katy Beckermann, MD
Katy Beckermann, MD@katy_beckermann

Perioperative EV plus pembrolizumab is now approved for every MIBC patient headed for cystectomy, cisplatin-eligible or not. The FDA expanded the label today on the strength of a head-to-head win over cisplatin-based chemo, the standard we've used for 20 years.

🟢 FDA Approval Jul 10, 2026
David H Aggen, MD PhD
David H Aggen, MD PhD@Dr_Aggen

🚨 Updates for MIBC 🚨 FDA approves neoadjuvant + adjuvant EV+pembro for muscle-invasive bladder cancer — regardless of cisplatin eligibility. The first platinum-free regimen to beat SOC chemo in ~25 yrs. EV-304 (KEYNOTE-B15): 📉 EFS HR 0.53 (47% ↓ recurrence/progression/death)

🟢 FDA Approval Jul 10, 2026
Tom Powles
Tom Powles@tompowles1

3 studies testing Perioperative immune bases therapy (EVP or Gem/Cis/Durva) in muscle invasive bladder all have shown an OS advantage vs standard of care. KN905 (EVP) is distinct in that it’s in a…

👁 9.9K ♡ 170 ↻ 77 Feb 27, 2026
Tom Powles
Tom Powles@tompowles1

KN-B15/EV303: R3 Perioperative EVP vs Gem/cis in MIBC shows EFS HR 0.53 (0.41–0.70), OS HR 0.65 (0.48-0.89), pCR 56% vs 33%, G3+ tox 76% vs 67% #GU26. About half the patients completed 9 cycles of…

👁 7.7K ♡ 131 ↻ 55 Feb 27, 2026
Marta Orozco Belinchon
Marta Orozco Belinchon@OrozcoBelinchon

Is this the end of cisplatin in MIBC?

With the results from NIAGARA, KEYNOTE-B15/EV-304, and KEYNOTE-905/EV-303, along with the emergence of ctDNA in IMvigor011, it is becoming increasingly…

👁 6.3K ♡ 51 ↻ 19 Mar 21, 2026
Javier Puente
Javier Puente@docjavip

KEYNOTE-B15/EV-304 trial is practice-changing: periop EV+ pem:
🔥 47% reduction in risk of events (HR 0.53)
🔥 Significant OS benefit (HR 0.65)
🔥 pCR 55.8% vs 32.5%
A true paradigm shift for…

👁 4.9K ♡ 55 ↻ 21 Feb 27, 2026
Jacob Plieth
Jacob Plieth@JacobPlieth

A "slam-dunk home run" from $PFE $ALPMF Padcev. @ByMadeleineA on #GU26 late-breaking Keynote-B15 data, via @ApexOnco -&gt; https://t.co/O6ynVa4H7H $MRK

👁 4.8K ♡ 11 ↻ 5 Feb 27, 2026
Urology Times
Urology Times@UrologyTimes

🚨 KEYNOTE-B15: Perioperative EV + pembrolizumab significantly improved EFS, OS, &amp; pCR vs cisplatin chemo in cisplatin-eligible MIBC, marking the first regimen in ~25 years to surpass the…

👁 3.1K ♡ 6 ↻ 1 Feb 27, 2026
Sophia Kamran, MD
Sophia Kamran, MD@sophia_kamran

Day 2 (#bladder!) for @ASCO #GU26!!
Really nice discussion by @DrTylerStewart of the KEYNOTE-B15 study
⭐️practice-changing, let&#x27;s put discussion of ddMVAC to rest https://t.co/0f7ZAfPFOL

👁 3K ♡ 20 ↻ 9 Feb 27, 2026
David H Aggen, MD PhD
David H Aggen, MD PhD@Dr_Aggen

UC Takeaways from #ASCOGU26
1) KEYNOTE-B15 is a landmark. Periop EV+pembro vs gem/cis in cis-eligible MIBC: EFS HR 0.53, pCR 55.8% vs 32.5%, OS benefit. First regimen to displace cisplatin in…

👁 2.9K ♡ 42 ↻ 19 Mar 1, 2026
Mirrors of Medicine
Mirrors of Medicine@mirrorsmed

🔥 Presented at #EAU2026: new KEYNOTE-B15 / EV-304 data

✅After previously reported survival benefits, new data now also highlight improved pathological downstaging and disease-free survival with…

👁 2.9K ♡ 31 ↻ 21 Mar 15, 2026
Dr Amol Akhade
Dr Amol Akhade@SuyogCancer

Cross trial comparison and where we are heading in MIBC @asco #gu26 @DrChoueiri @dr_yakupergun @brunolarvol @OncoAlert @OncBrothers https://t.co/5gzECBkrrf

👁 2.9K ♡ 39 ↻ 16 Feb 27, 2026
Regulatory

FDA Approval — July 10, 2026

FDA APPROVEDPerioperative EV + pembrolizumab for MIBC — regardless of cisplatin eligibility

On July 10, 2026, the FDA approved enfortumab vedotin-ejfv (Padcev) in combination with pembrolizumab (Keytruda) — or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) — as perioperative treatment (neoadjuvant before, and adjuvant after, radical cystectomy) for adults with muscle-invasive bladder cancer (MIBC). This is a label expansion to cisplatin-eligible patients: the regimen is now approved for all MIBC patients who are candidates for cystectomy, regardless of cisplatin eligibility. The approval is based on the Phase 3 EV-304 / KEYNOTE-B15 trial (NCT04700124) in cisplatin-eligible MIBC — the first platinum-free perioperative regimen to beat standard-of-care neoadjuvant gemcitabine + cisplatin in ~25 years (EFS HR 0.53; pCR 55.8% vs. 32.5%). It was granted early (the PDUFA date was August 17, 2026). This expands on the prior approval of November 21, 2025, when the regimen was approved only for cisplatin-ineligible MIBC (based on EV-303/KEYNOTE-905).

📄 Source: FDA approval announcement →
📄 Source: ClinicalTrials.gov — EV-304 (NCT04700124) →
Trial Background

About the KEYNOTE-B15 / EV-304 Trial

Practice-changing and now FDA-approved (July 10, 2026). EV+P in cisplatin-eligible MIBC extends the perioperative IO paradigm beyond NIAGARA (durvalumab+GC). Direct competition between ADC+IO (KEYNOTE-B15) and chemo+IO (NIAGARA) for the cisplatin-eligible population. On July 10, 2026 the FDA expanded the perioperative EV+pembro label to cisplatin-eligible patients, making the regimen available for adult MIBC radical-cystectomy candidates regardless of cisplatin eligibility — building on the November 21, 2025 approval in the cisplatin-ineligible population.

📄 NCT04700124 📄 Pivotal Publication
Study Design

Trial Methodology & Results

Event-Free Survival (EFS) — Co-Primary Endpoint

Event-free survival HR was 0.53 (95% CI 0.41-0.70, P<0.0001) favoring enfortumab vedotin + pembrolizumab. 24-month EFS rate: 79.4% vs. 66.2%. Median EFS not reached with EV+P vs. 48.5 months with gem/cis. pCR (pathological complete response) rate: 55.8% vs. 32.5%.

✓ EFS HR 0.53; pCR 55.8% vs. 32.5%

📄 Source: KOL commentary on X →

Overall Survival (OS)

OS improvement reported — approximately 35% risk reduction favoring EV+P vs. chemotherapy (OS HR 0.65, 95% CI 0.48-0.89, 1-sided P=0.0029). Both median OS values not reached. FDA approved the perioperative EV+pembro regimen for cisplatin-eligible MIBC on July 10, 2026.


📄 Source →

Safety & Tolerability

Grade ≥3 adverse events occurred in 75.7% with EV+P vs. 67.2% with gem/cis. Key AEs: EV-related skin reactions (14.1% G≥3), peripheral neuropathy; pembrolizumab-related skin reactions (13.9% G≥3). Profile manageable and consistent with individual agents. Across EV-303 and EV-304, the most common (≥30%) treatment-related adverse events were pruritus, alopecia, diarrhea, and anemia; no new safety signals were observed. Prescribing warnings include immune-mediated reactions, serious skin reactions, hyperglycemia, pneumonitis/interstitial lung disease, peripheral neuropathy, ocular disorders, infusion-site extravasation, and embryo-fetal toxicity.

G≥3 AEs 75.7% vs. 67.2% (manageable)

📄 Source →

Clinical Implications

✅ FDA approved (July 10, 2026) — a paradigm shift in cisplatin-eligible MIBC. Perioperative EV+pembro is now FDA-approved for adult MIBC patients who are radical-cystectomy candidates, regardless of cisplatin eligibility — the first platinum-free perioperative regimen to displace cisplatin-based chemotherapy in ~25 years. EV+P extends the perioperative IO paradigm beyond NIAGARA (durvalumab+GC), with direct competition between ADC+IO (KEYNOTE-B15) and chemo+IO (NIAGARA) for the cisplatin-eligible population. This label expansion builds on the November 21, 2025 approval for cisplatin-ineligible MIBC (EV-303/KEYNOTE-905).

Frequently Asked Questions

KEYNOTE-B15 / EV-304 FAQ

What is the KEYNOTE-B15 / EV-304 trial?

KEYNOTE-B15 / EV-304 (NCT04700124) is a Phase 3 randomized trial of perioperative enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda) versus neoadjuvant gemcitabine-cisplatin chemotherapy in patients with muscle-invasive bladder cancer who are candidates for radical cystectomy. Event-free survival and pathologic complete response were co-primary endpoints.

What were the main efficacy results of KEYNOTE-B15 / EV-304?

Event-free survival strongly favored the enfortumab vedotin plus pembrolizumab regimen (HR 0.53; 95% CI 0.41-0.70; 24-month EFS 79.4% vs 66.2%), the pathologic complete response rate was 55.8% versus 32.5% with chemotherapy, and overall survival improved with a hazard ratio of 0.65 (95% CI 0.48-0.89), about a 35% reduction in the risk of death.

Is perioperative EV plus pembrolizumab FDA approved for bladder cancer?

Yes. On July 10, 2026 the FDA approved perioperative enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda) for adults with muscle-invasive bladder cancer who are candidates for radical cystectomy, regardless of cisplatin eligibility - the first platinum-free perioperative regimen to displace cisplatin-based chemotherapy in this setting in about 25 years.

What is the safety profile of the KEYNOTE-B15 / EV-304 regimen?

Grade >=3 adverse events occurred in 75.7% of patients on enfortumab vedotin plus pembrolizumab versus 67.2% with gemcitabine-cisplatin. Key toxicities included enfortumab-vedotin-related skin reactions and peripheral neuropathy and pembrolizumab-related skin reactions; the profile was consistent with the individual agents, with no new safety signals reported.

How does KEYNOTE-B15 / EV-304 relate to NIAGARA and the broader perioperative bladder cancer landscape?

KEYNOTE-B15 / EV-304 extends the perioperative immunotherapy paradigm in MIBC beyond NIAGARA (durvalumab plus gemcitabine-cisplatin). It is notable for being a platinum-free antibody-drug-conjugate-plus-immunotherapy regimen that outperformed cisplatin-based chemotherapy, broadening options for radical-cystectomy candidates regardless of cisplatin eligibility.

Major Media & Publications

KEYNOTE-B15 / EV-304 in the News

Publication
KEYNOTE-B15/EV-304 ASCO GU 2026 LBA630
JCO/ASCO GU 20262026-02-15
 Press Release
Keytruda + Padcev reduces risk of EFS events by 47% and death by 35% in cisplatin-eligible MIBC
Merck2026
 Press Release
FDA Grants Priority Review for Keytruda + Padcev in Cisplatin-Eligible Perioperative MIBC
Merck2026-04
 Media Coverage
Perioperative Enfortumab Vedotin + Pembrolizumab May Reduce Recurrence Risk in MIBC
The ASCO Post2026-02
 Media Coverage
KEYNOTE-B15 — EV+P Improves OS, EFS, pCR Rates Over Chemotherapy
ASCO Daily News2026
Physician Opinions

Key KOL Sentiments — KEYNOTE-B15 / EV-304

DoctorSentimentComment
Toni Choueiri, MD ● POSITIVE Now, the combo of EV-Pembro is @US_FDA approved for all muscle-invasive bladder cancer @OncoAlert @AUC3_Official @Merck @BladderCancerUS @OncoBellmunt @bergsa83 @mouwlab
Katy Beckermann, MD ● POSITIVE Perioperative EV plus pembrolizumab is now approved for every MIBC patient headed for cystectomy, cisplatin-eligible or not. The FDA expanded the label today on the strength of a head-to-head win over cisplatin-based chemo, the standard we've used for 20 years.
David H Aggen, MD PhD ● POSITIVE 🚨 Updates for MIBC 🚨 FDA approves neoadjuvant + adjuvant EV+pembro for muscle-invasive bladder cancer — regardless of cisplatin eligibility. The first platinum-free regimen to beat SOC chemo in ~25 yrs. EV-304 (KEYNOTE-B15): 📉 EFS HR 0.53 (47% ↓ recurrence/progression/death)
Matt Campbell MD, MS ● POSITIVE What a start to bladder day at #GU26 @MattGalsky KEYNOTE B-15 first phase 3 to surpass cisplatin for NAC in MIBC. Now both trials with EVP in NAC space with consistently strong pCR, EFS, and OS allowing us to dream big about optimal bladder sparing designs. Congrats to all https://t.co/v6Ai4b6yqI
Dillon Cockrell, MD ● POSITIVE Big day for #bladdercancer at #GU26 kicks off with much anticipated KNB15/EV304 trial for periop EV plus pembro vs neoadjuvant gem/cisplatin in MIBC. Significant improvements in both EFS and OS (HR 0.65) with pCR 55 vs 32% favoring EV-P. New SOC for #MIBC! Next questions: How https://t.co/WGa8BuqGdr
Ashish M. Kamat, MD, MBBS ● POSITIVE @tompowles1 @LauraBukavinaMD @DrKarineTawagi @MattGalsky Great points. B15 establishes the potency of EVP but we have to be careful not to conflate maximum systemic efficacy with total local clearance - they’re not the same thing, and the 55.8% pCR rate, impressive as it is, didn’t eliminate the need for the adjuvant tail to drive EFS
Alfonso Gómez de Liaño ● POSITIVE Congrats @MattGalsky on a great presentation of KEYNOTE-B15. Impressive, practice-changing data. First platinum-free regimen to improve survival in cis-eligible MIBC (EFS HR 0.53; OS HR 0.65) with unprecedented pCR ~56%. These results support the perioperative approach as a https://t.co/kML6WYRCdd
Mutlu Hizal ● POSITIVE @SuyogCancer @DrChoueiri @tompowles1 @DrYukselUrun @ASCO @OncoAlert @OncBrothers Well said! We definitely need the answer to this question—lots more to discuss. But first, let’s enjoy a couple of days of that 55% pCR ☺️
Marta Orozco Belinchon ● NEUTRAL Is this the end of cisplatin in MIBC? With the results from NIAGARA, KEYNOTE-B15/EV-304, and KEYNOTE-905/EV-303, along with the emergence of ctDNA in IMvigor011, it is becoming increasingly difficult to defend it as the sole backbone of perioperative treatment. Are we truly https://t.co/RzCBjhFS3Q
Javier Puente ● NEUTRAL KEYNOTE-B15/EV-304 trial is practice-changing: periop EV+ pem: 🔥 47% reduction in risk of events (HR 0.53) 🔥 Significant OS benefit (HR 0.65) 🔥 pCR 55.8% vs 32.5% A true paradigm shift for cisplatin-eligible MIBC. Honored to be part of this milestone with our HCSC team #GU26 https://t.co/76iCUFu7fd
Jacob Plieth ● NEUTRAL A "slam-dunk home run" from $PFE $ALPMF Padcev. @ByMadeleineA on #GU26 late-breaking Keynote-B15 data, via @ApexOnco -&gt; https://t.co/O6ynVa4H7H $MRK
Urology Times ● NEUTRAL 🚨 KEYNOTE-B15: Perioperative EV + pembrolizumab significantly improved EFS, OS, &amp; pCR vs cisplatin chemo in cisplatin-eligible MIBC, marking the first regimen in ~25 years to surpass the long-standing standard. #GU26 @MattGalsky https://t.co/gnWcfkxHMg
Sophia Kamran, MD ● NEUTRAL Day 2 (#bladder!) for @ASCO #GU26!! Really nice discussion by @DrTylerStewart of the KEYNOTE-B15 study ⭐️practice-changing, let's put discussion of ddMVAC to rest https://t.co/0f7ZAfPFOL
David H Aggen, MD PhD ● NEUTRAL UC Takeaways from #ASCOGU26 1) KEYNOTE-B15 is a landmark. Periop EV+pembro vs gem/cis in cis-eligible MIBC: EFS HR 0.53, pCR 55.8% vs 32.5%, OS benefit. First regimen to displace cisplatin in curative-intent bladder cancer in ~25 yrs. https://t.co/VQgB23JeVl
Mirrors of Medicine ● NEUTRAL 🔥 Presented at #EAU2026: new KEYNOTE-B15 / EV-304 data ✅After previously reported survival benefits, new data now also highlight improved pathological downstaging and disease-free survival with perioperative enfortumab vedotin + pembrolizumab in cisplatin-eligible MIBC while https://t.co/eJbNEQpQw3
Dra. María Natalia Gandur Quiroga ● NEUTRAL 🔷 EV/P Improves EFS &amp; OS vs Cis/Gem — What Does It Mean? Discussion by Tyler F. Stewart, MD @MattGalsky @TomPowles1 @OncoAlert #ASCOGU26 #GU26 #BladderCancer KEYNOTE-B15 confirms: 🔹 EFS HR 0.53 → 2-yr EFS 79% vs 66% 🔹 OS HR 0.65 → 2-yr OS 87% vs 81% Across MIBC trials: • https://t.co/RXpf5xvPE2
Toni Choueiri, MD ● NEUTRAL Major practice changing peri-op readout by @MattGalsky, KEYNOTE-B15/EV-304: EV+pembro peri-op vs neoadj GC + surgery → trial met endpoints with significant EFS (HR 0.53, p&lt;0.001) + OS (0.65, p =0.0029) + pCR improvement (23.4% sig difference) @OncoAlert @OncBrothers #GU26 https://t.co/9Cx3nAlVlT
Toni Choueiri, MD ● NEUTRAL High-yield discussion by @DrTylerStewart how to place peri-op EV+pembro in cis-eligible MIBC, and where HER2 ADCs may land #GU26 #BladderCancer @OncoAlert @OncBrothers https://t.co/Fu4L1BqDx1
Martín Angel ● NEUTRAL 🆕 options for our patients!!! KEYNOTE-B15: Neo/adjuvant EV + pembro for participants with #MIBC cis-eligible study @MattGalsky @tompowles1 EFS: NR 🆚48.5 months (HR:0.53‼️) 2y estimated OS: 86.9 vs 81.3 %. (HR:0.65) @Blatam_urology @UroTarget #GU26 @ASCO https://t.co/ipJ2XiCocv
Maite Bourlon ● NEUTRAL DAY 2: #Urothelialcancer @asco #GU26 🟢 KEYNOTE-B15 EV + pembro cisplatin-eligible MIBC 📢 TOP abstract @MattGalsky 🧑‍🔬 RC48G001 P2 disitamab HER2+ previously tx aUC @tompowles1 🌅 SunRISe-2 Gem-intravesical +cetre vs ChemoRT in MIBC @AndreaNecchi @OncoAlert @oncodaily https://t.co/UV6KRpMOJi
Katy Beckermann ● NEUTRAL 🔥 KEYNOTE-B15 is practice-changing and redefines perioperative management in cis-eligible MIBC. EV + pembrolizumab significantly improved: 📊 pCR: 55.8% vs 32.5% 📊 EFS: HR 0.53 📊 OS: HR 0.65 Yes, toxicity was higher (grade ≥3 AEs: 76% vs 67%), but this is the clearest https://t.co/dgd6epCLQW
MV Chandrakanth ● NEUTRAL KEYNOTE-B15 (EV-304): EV + Pembro beats Cis+Gem in MIBC • EFS HR 0.53 • OS HR 0.65 • pCR 56% vs 33% 58.9% control pts received subsequent therapy — nivolumab % unknown. Perioperative shift. #BladderCancer #GU26 #UroOnc https://t.co/9usmbKoqQy
Karine Tawagi MD ● NEUTRAL Groundbreaking KN-B15 for EVP in cis-eligible MIBC 👤 most T3/T4a, 90% pure urothelial 🎖️ EFS HR 0.53, OS HR 0.65, pCR 55.8% vs 32.5% ⚠️¾ grade 3 TEAE, 25% stopped NA EVP &amp; 28.6% adj EVP d/t TEAE ‼️36% neuropathy, 63% skin, 23% 👁️ ❓how many got IO in control arm https://t.co/yBE2uQrfKp
Zach Klaassen ● NEUTRAL ⚡️UC Oral Abstract: Neoadj/adjuv EVP for cisplatin-eligible MIBC: Ph 3 KEYNOTE-B15 trial #GU26 @urotoday 📢Practice Changing Trial EVP vs Cis/Gem: 📍EFS: HR 0.53, 95% CI 0.41-0.70 📍OS: HR 0.65, 95% CI 0.48-0.89 📍pCR rate: 55.8% vs 32.5% 📍No unexpected toxicity https://t.co/JCM0bnRxS7
Tom Powles ● NEUTRAL 3 studies testing Perioperative immune bases therapy (EVP or Gem/Cis/Durva) in muscle invasive bladder all have shown an OS advantage vs standard of care. KN905 (EVP) is distinct in that it’s in a cisplatin ineligible population (accounting for the poor performance of the control https://t.co/qmrJoN2inz
Tom Powles ● NEUTRAL KN-B15/EV303: R3 Perioperative EVP vs Gem/cis in MIBC shows EFS HR 0.53 (0.41–0.70), OS HR 0.65 (0.48-0.89), pCR 56% vs 33%, G3+ tox 76% vs 67% #GU26. About half the patients completed 9 cycles of EVP. These are great results. Gem/cid is harder to beat when not all patients are https://t.co/pXWvb1wSpe
Dr Amol Akhade ● NEUTRAL Cross trial comparison and where we are heading in MIBC @asco #gu26 @DrChoueiri @dr_yakupergun @brunolarvol @OncoAlert @OncBrothers https://t.co/5gzECBkrrf
Dr Amol Akhade ● NEUTRAL Keynote B15 . Nice curves for Efs and Os . Question is How Many got nivolumab on progression in Gem Cis arm and what was their outcome ? 🤔 anyone has that data ? @DrChoueiri @tompowles1 @DrYukselUrun @ASCO #GU26 @OncoAlert @OncBrothers https://t.co/CMWKjwytdP
Dra. María Natalia Gandur Quiroga ● NEUTRAL 🔷 KEYNOTE-B15 / EV-304 (LBA630) Presented by Matthew D. Galsky, MD #ASCOGU26 #GU26 #BladderCancer @OncoAlert Perioperative EV + pembrolizumab vs neoadjuvant cisplatin + gemcitabine in cisplatin-eligible MIBC: 🔹 EFS: HR 0.53 (95% CI 0.41–0.70; P&lt;0.001)   24-mo EFS 79.4% vs https://t.co/4kQaEFnXhL
Oncology Brothers ● NEUTRAL GU @ASCO highlights from #GU26 with @PGrivasMDPhD ✅ CREST/POTOMAC (update) ✅ EV304/KeynoteB15 (new SoC) ✅ LITESPARK-011 &amp; 022 ✅ CAPItello-281 Full 🗣️: ⭐️ On OncBrothers &amp; @OncUpdates website ⭐️ “Oncology Brothers” podcast #OncTwitter #MedTwitter #gusm @OncoAlert https://t.co/ToC5o67KZI
LARVOL ● NEUTRAL Ahead of @ASCO GU 2026, we analyzed how leading AI models ranked the most discussed Genitourinary cancer trials and compared those signals with OncoBuzz (views on oncologists’ posts on 𝕏). AI alignment was strongest for EORTC-1333/PEACE-3, KEYNOTE-B15/EV-304, LITESPARK-022, and https://t.co/5FwqQhoijg
ONCOassist® | The go-to oncology app ● NEUTRAL 🎥 Oncology Bytes | ASCO GU 2026 Dr. Shreyas Kalantri breaks down the most important trials from ASCO GU 2026 covering: • KEYNOTE-B15 in bladder cancer • Belzutifan trials in RCC • PEACE-3 in prostate cancer 📺 Watch the highlights now: https://t.co/myjts21ICg https://t.co/CZuf7bqEg4
Carlos Alvarez ● NEUTRAL Discussion on KEYNOTE-B15 by @DrTylerStewart at #GU26 https://t.co/QNsucsQKO0